Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs

ZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today provided an update on its strategy and progress to implement a suite of U.S. Food and Drug Administration (FDA) aligned New Approach Methodologies (NAMs) across its preclinical research and development programs, potentially enabling faster clinical advancement while significantly reducing animal testing. This strategic implementation positions VERAXA ahead of the FDA’s 2025 roadmap, which encourages the phased reduction and ultimate replacement of animal testing in favor of human-relevant, non-animal and non-clinical test methods for developing safe and effective therapies.

NAMs encompass a range of technologies, including cell-based assays, organ-on-chip systems, computational modeling and ex vivo tissue models, designed to more accurately predict human biological responses while reducing dependence on animal models. Beyond this regulatory alignment, the shift toward more sustainable and ethical research practices is also expected to reduce development costs and timelines, for example, by bypassing certain non-human primate (NHP) toxicology studies traditionally required ahead of clinical development.

“We see NAMs as not just a regulatory obligation, but also as a scientific opportunity,” said Christoph Erkel, Ph.D., Chief Scientific Officer of VERAXA. “We’ve been investing in translational, human-relevant model systems well ahead of the FDA’s 2025 roadmap, and we see this shift as beneficial and a win-win situation for both science and sustainability. Reducing our reliance on animal studies, particularly NHP toxicology testing, allows us to generate more clinically predictive data, move faster, and do so more efficiently and sustainably.”

VERAXA has been building a multi-layered panel of NAMs to characterize and de-risk its pipeline of BiTAC (bi-targeted tumor-associated cytotoxicity) based T cell engagers (BiTAC-TCEs), BiTAC-based antibody drug conjugates (BiTAC-ADCs) and bispecific antibody-drug conjugates (bsADCs) technologies. At the AACR Annual Meeting 2026, the Company presented initial data on its most advanced BiTAC-TCE program. In those studies, the candidate performed as intended in vitro and in vivo, attacking cancer cells that displayed both target molecules while sparing cells expressing only one of the two, with a safety profile that was superior, and efficacy that matched, a more traditional TCE, pointing to the possibility of a meaningfully improved therapeutic index. The in vitro results came from three-dimensional, cell line-derived spheroid models, which recapitulate solid tumor architecture more closely than two-dimensional culture. VERAXA has since generated new spheroid data demonstrating consistent predictivity of T cell engagement specificity across diverse cancer cell lines and validating the model for IND-enabling studies, further reinforcing this model’s translational value ahead of clinical development.

VERAXA further evaluated its lead BiTAC-TCE and bsADC candidates in an ex vivo panel of ten low-passage patient-derived xenograft models of non-small cell lung cancer, models that closely preserve the molecular characteristics, heterogeneity, and therapeutic response of the original tumors. Because these assays draw on tumor material from a small number of donor mice and can be split into many parallel patient samples, the panel required only about ten mice in total, versus an estimated 200 or more for comparable in vivo efficacy studies.

Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, while relevant controls, including commercial T cell engagers against non-expressed targets, showed only minimal activity, providing strong evidence that VERAXA’s dual-targeting approach extends beyond cell line models into clinically meaningful anti-tumor activity, validating the need for simultaneous dual-target engagement and reinforcing BiTAC as a next-generation approach to T cell redirection. This ex vivo platform demonstrates how VERAXA’s NAM strategy reduces both animal use and preclinical cycle time without compromising clinical relevance.

About VERAXA Biotech AG (NASDAQ: VRXA)

VERAXA is building a premier engine for the discovery and development of next-generation antibody-based cancer therapeutics, powered by a suite of transformative technologies and guided by rigorous quality-by-design principles. The company is rapidly advancing its pipeline of conditionally active T cell engagers (BiTAC-TCEs), bispecific antibody-drug conjugates (bsADCs), and proprietary BiTAC formats into clinical development. Uniquely, VERAXA has implemented FDA-aligned New Approach Methodologies across all preclinical programs, enabling faster clinical advancement while reducing reliance on animal testing. Founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), a world-renowned institution for pioneering life science research, VERAXA combines innovation with responsible research practices.

For regular updates about VERAXA Biotech, visit www.veraxa.com or follow us on LinkedIn, X (formerly known as Twitter) and Bluesky.

BiTAC® is a registered trademark of VERAXA Biotech GmbH.

Forward-looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that address activities, events, or developments that VERAXA Biotech AG (the “Company”) intends, expects, plans, projects, believes, or anticipates will or may occur in the future are forward-looking statements, including the Company’s ability to utilize NAMS across its preclinical research and development programs to enable faster clinical advancement and the ability of its technological platform to produce transformative therapeutics. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements contained on this press release should be evaluated together with the many uncertainties that affect the Company’s business, particularly those identified or referenced in the risk factors section of the Company’s most recent Annual Report on Form 20-F and any subsequent reports on Form 6-K. These documents are available from the Securities and Exchange Commission, the Company website or from Company Investor Relations.

In addition, any information contained in this press release was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, the company will not update the information contained in this press release and investors should not rely upon the information as current or accurate after the presentation date.

Attachment

CONTACT: Contact
VERAXA Biotech AG – Corporate 
 Christoph Antz, Ph.D.
 Chief Executive Officer, Co-Founder
 investors@veraxa.com
 
For Media and Investors – U.S.
 Brandon Weiner
 ICR Healthcare
 VERAXA@icrhealthcare.com
 
For Media and Investors – EU
 Mario Brkulj
 investors@veraxa.com

LONDON, Oct. 07, 2026 (GLOBE NEWSWIRE) — Marex Group Limited (‘Marex’ or the ‘Group’; NASDAQ: MRX) today announces that Chair of the Board Robert Pickering has stepped down from the Group Board, having overseen an exceptional period of growth and change during his appointed three-year term.

Robert joined the Group Board in September 2021 before becoming Senior Independent Director in March 2022 and Chair of the Board in October 2023. During Robert’s tenure, Marex has undergone a period of significant growth and transformation, including its successful IPO in April 2024, and development into a leading diversified global financial services platform.

Robert has been succeeded as Chair by John Pietrowicz, a current member of the Board and Chair of the Group’s Mergers and Acquisitions Committee. John joined the Group Board in April 2024, having previously served as Chief Financial Officer of CME Group from 2014 until 2023. His extensive experience at CME, including overseeing its acquisition strategy, brings valuable expertise in financial markets infrastructure and M&A. He is also a well-known figure to the Group’s analysts and investor base. John will work closely with Robert to ensure a smooth transition.

Robert Pickering, outgoing Chair: “It has been fascinating to be part of Marex’s progression over the past five years, helping it evolve from a small private company into a Nasdaq-listed business with a market capitalization in excess of $5 billion. Marex has exciting prospects and I wish it every success in the future.”

Ian Lowitt, Group CEO: “On behalf of the Board and everyone at Marex, I would like to thank Robert for his outstanding contribution. Marex has been on an incredible journey and Robert’s experience, judgment and counsel have been invaluable. Robert guided the firm through the listing process, successful IPO on Nasdaq, and subsequent diversification and growth. We are grateful for his leadership and commitment to Marex and wish him all the very best for the future. I am excited to work with John as our new Chair as we embark on our next chapter and as we seek to extend our track record of sustainable growth.”  

About Marex: Marex Group Limited (NASDAQ: MRX) provides market access, infrastructure services and essential liquidity to clients across global commodity and financial markets. The Group provides comprehensive breadth and depth of coverage across four services: Clearing, Agency and Execution, Market Making and Hedging and Investment Solutions. It has a leading franchise in many major metals, energy and agricultural products, with access to more than 60 exchanges. Marex has over 3,400 active clients, including some of the largest commodity producers, consumers and traders, banks, hedge funds and asset managers. With more than 50 offices worldwide, the Group has over 3,000 employees across Europe, Asia and the Americas. For more information visit www.marex.com.

Enquiries please contact:
Marex: Nicola Ratchford / Adam Strachan
+44 778 654 8889 / +1 914 200 2508
nratchford@marex.com / astrachan@marex.com

FTI Consulting US / UK
+1 716 525 7239 / +44 7976870961
marex@fticonsulting.com

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the board changes and the future growth of the business. In some cases, these forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “would,” “is/are likely to” or other similar expressions.

These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the risks discussed under the caption “Risk Factors” in our Annual Report on Form 20-F for the year-ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) and our other reports filed with the SEC. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

PHOENIX, Oct. 07, 2026 (GLOBE NEWSWIRE) — Reliance, Inc. (NYSE:RS) announced today that it will report third quarter 2026 financial results for the period ended September 30, 2026, on Wednesday, October 21, 2026, after the market closes. Reliance management will host a conference call on Thursday, October 22, 2026, at 11:00 a.m. Eastern Time. The call will be broadcast live over the Internet hosted on the Investors section of the Company’s website at reliance.com.

Reliance, Inc. Third Quarter 2026 Conference Call Details

DATE: Thursday, October 22, 2026
   
TIME: 8:00 a.m. Pacific Time
10:00 a.m. Central Time
11:00 a.m. Eastern Time
   
DIAL-IN: (877) 407-0792 (U.S. and Canada)
(201) 689-8263 (International)
   
CONFERENCE ID: 13762971
   
WEBCAST: https://viavid.webcasts.com/starthere.jsp?ei=1777674&tp_key=2f5a1b60e5
       

For those unable to participate during the live broadcast, a replay of the call will also be available beginning that same day at 2:00 p.m. Eastern Time until 11:59 p.m. Eastern Time on November 5, 2026, by dialing (844) 512-2921 (U.S. and Canada) or (412) 317-6671 (International) and entering the conference ID: 13762971. The webcast will remain posted on the Investors section of Reliance’s website at reliance.com for 90 days.

About Reliance, Inc.
Founded in 1939, Reliance, Inc. (NYSE: RS) is a leading global diversified metal solutions provider and the largest metals service center company in North America. Through a network of approximately 310 locations in 41 states and 10 countries outside of the United States, Reliance provides value-added metals processing services and distributes a full-line of over 100,000 metal products to more than 125,000 customers in a broad range of industries. Reliance focuses on small orders with quick turnaround and value-added processing services. In 2025, Reliance’s average order size was $3,120, approximately 49% of orders included value-added processing, and approximately 40% of orders were delivered within 24 hours. Reliance’s press releases and additional information are available on the Company’s website at reliance.com.

CONTACT:
(213) 576-2428
investor@reliance.com

or Addo Investor Relations
(310) 829-5400

EcoVadis logo

EcoVadis logo
EcoVadis logo

News release

Atos awarded EcoVadis Gold Medal, ranking among the top 5% of companies assessed worldwide

Paris, France, October 7, 2026 – Atos, a global leader in AI-powered digital transformation, today announces that it has been awarded the EcoVadis Gold Medal for its sustainability performance. This recognition places Atos among the top 5% of all companies assessed by EcoVadis worldwide over the previous 12 months.

With an improved overall score of 85 out of 100, one point higher than in the previous assessment, Atos continues to demonstrate the strength and maturity of its sustainability management system. The assessment covers four key areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.

Atos achieved particularly strong results in Ethics, with a score of 97 out of 100, Environment, with 96 out of 100, and Sustainable Procurement, with 86 out of 100.

“The EcoVadis Gold Medal recognizes the sustained commitment of our teams to embedding sustainability across our operations and business relationships. By improving our overall score to 85 out of 100 and ranking among the top 5% of companies assessed worldwide, Atos has once again demonstrated the strength of its sustainability management system and its commitment to continuous progress across its environmental, social, ethical and responsible procurement priorities,” said Alexandra Knupe, Group Head for Corporate Social Responsibility, Atos Group.

The EcoVadis assessment is an important independent benchmark of Atos’ sustainability management system. It supports the Group’s commitment to transparent and responsible business practices and complements its broader sustainability strategy and reporting framework.

For further information on Atos Group’s sustainability commitments and performance, please refer to its latest Universal Registration Document.

###

About Atos

Atos is Atos Group’s brand dedicated to end-to-end, secure and AI-accelerated digital services. Atos designs, develops and operates digital environments that are critical to performance, resilience and sovereignty. The company helps public and private organizations around the world maintain control of their data and infrastructure, while meeting their compliance requirements.

With more than 52,000 employees serving more than 4,500 customers in 54 countries, Atos supports the modernization of IT systems, accelerates cloud and data transformation, strengthens cybersecurity and deploys secure digital workplaces for the benefit of its customers, their employees and society. Atos also offers consulting and support services through its Atos Amplify brand.

As a trusted partner in the management of complex and critical environments, Atos supports organizations in highly regulated and sovereign contexts.

About Atos Group

Atos Group is a global leader in digital transformation with nearly 54,000 employees and annual revenues of nearly €7.2 billion. With a commercial presence in 54 countries, it operates under two brands: Atos for services and Eviden for products and systems. As the European leader in cybersecurity and a leader in the cloud sector, Atos Group is committed to a secure and decarbonized future. It offers tailor-made and integrated solutions, accelerated by AI, for all sectors of activity. Atos Group is listed on Euronext Paris.

Press contact: Laurent Massicot – laurent.massicot@atosgroup.com

Attachments

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Pollen Street Group Limited
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Joint Broker to Pollen Street Group Limited
(d)        Date dealing undertaken: 06th October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales Total number of securities Highest price per unit paid/received Lowest price per unit paid/received
Ordinary shares Purchases 35,964 888 888
Ordinary shares Sales 35,964 888 888

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION
        
(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 07th October 2026
Contact name: Abhishek Gawde
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 7 OCTOBER 2026 AT 13.30 P.M. EET, MAJOR SHAREHOLDER ANNOUNCEMENT

Notification under Chapter 9, Section 10 of the Securities Market Act: Holdings of Liedon Säästöpankkisäätiö in Oma Savings Bank Plc decreased below 10 percent

On 7 October 2026, Oma Savings Bank Plc (OmaSp) received a notification under Chapter 9, Section 5 of the Securities Market Act (SMA) from Liedon Säästöpankkisäätiö (business ID 0134703-0), according to which Liedon Säästöpankkisäätiö’s holding and voting rights in OmaSp decreased below 10 percent threshold on 7 October 2026.

According to the announcement, Liedon Säästöpankkisäätiö sr owns 0 OmaSp shares, corresponding to 0 percent of OmaSp’s shares and votes.

OmaSp has one class of shares in which each share has one vote. The total number of shares is 33,356,729.

The holding of Liedon Säästöpankkisäätiö sr according to the announcement:

  % of shares and voting rights (A) % of shares and voting rights through financial instruments (B) Total of both in % (A+B) Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached 0 0 0 33 356 729
Positions of previous notification (if threshold crossed) 9,39 NA 9,39  

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Shares and voting rights:

Class/type of shares Number of shares and
voting rights
% of shares and
voting rights
ISIN code Direct (SMA 9:5) Indirect
(SMA 9:6 and 9:7)
Direct (SMA 9:5) Indirect
(SMA 9:6 and 9:7)
FI4000306733 0 0 0 0
A total 0 0

Oma Savings Bank Plc

Additional information:

Karri Alameri, CEO, tel. +358 20 758 3040, karri.alameri@omasp.fi

Distribution:

Nasdaq Helsinki Ltd
Major media
www.omasp.fi

Oma Savings Bank is a well-capitalised and profitable Finnish bank that serves over 200,000 personal and corporate customers through 48 branches across Finland and digital channels with approximately 600 experts. Oma Savings Bank’s key objective is a first-class customer experience through personal service and easy accessibility in both digital and traditional channels. Oma Savings Bank focuses primarily on retail banking and offers its customers a diverse range of banking services both through its own balance sheet and by intermediating products of its cooperation partners, such as credit, investment and loan protection products. Oma Savings Bank also engages in mortgage banking operations. The Shares of Oma Savings Bank are listed on the regulated market maintained by Nasdaq Helsinki. Oma Savings Bank is a part of S-Bank Group.

  • Initial results from four holes infill and extend mineralization in the North Pit Extension Zone
  • Results support drilling toward the west to improve geological and grade continuity
  • Drilling is ongoing with one drill rig turning, and the program now expected to total approximately 12,000 metres in about 40 holes

TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) — NorthWest Copper Corp. (“NorthWest” or the “Company”) (TSX-V: NWST) is pleased to report initial drill results from its 2026 exploration program at the Company’s 100% owned Kwanika project in British Columbia. The first four holes reported from the approximately 40-hole program were drilled along a section at the southern end of the North Pit Extension Zone and focused on infill drilling and extending mineralization.

The four holes achieved their objectives by infilling and extending mineralization along the section, highlighted by hole K-26-303, which intersected 41.7 metres grading 1.13% copper equivalent (“CuEq”) at a shallow depth. The results support drilling toward the west as an effective approach to improving geological and grade continuity. The results also show a higher gold to copper metal ratio, generally above one, in this area, underscoring the importance of gold as a potential economic driver. The broader 2026 program is designed to upgrade and potentially expand mineral resources in the Pit, North Pit Extension and Western Zones.

Drill Hole Highlights:
K-26-303  
North Pit Ext:  41.7 metres of 0.40% Cu and 0.67 g/t Au (1.13% CuEq) from 72.6 metres
K-26-304  
North Pit Ext: 16.0 metres of 0.31% Cu and 0.17 g/t Au (0.50% CuEq) from 82.0 metres
K-26-312  
North Pit Ext: 27.2 metres of 0.20% Cu and 0.64 g/t Au (0.90% CuEq) from 122.9 metres
K-26-340  
North Pit Ext: 47.4 metres of 0.30% Cu and 0.44 g/t Au (0.78% CuEq) from 169.6 metres

Paul Olmsted, CEO of NorthWest, stated: “These initial results are an encouraging start to our 2026 drill program and reinforce our strategy of improving the quality and confidence of the mineral resource. With a substantial amount of drilling still to be reported, we expect the program to continue building our geological understanding of the mineral resource.

Our work on the Kwanika-Stardust Preliminary Economic Assessment (“PEA”) has taken longer than originally anticipated as certain elements related to the varied and distinct mining areas being evaluated have required additional analysis. The Company and its consultants have made significant progress, and that work has identified a number of opportunities to optimize alternative mine sequencing and processing approaches to further inform and optimize the PEA. In parallel, we will continue to review results from the 2026 drill program as they become available, including today’s results, to assess their potential positive impact on the optimization work being undertaken as part of the PEA.”

2026 Kwanika Exploration Program

The 2026 exploration program includes approximately 40 drill holes totalling approximately 12,000 metres at the Kwanika Central deposit, with collar locations and reported section line shown in Figure 1.

Figure 1: Kwanika Central 2026 drill hole location map

Figure 1

The objective of the 2026 drill program is to upgrade and expand mineral resources through shallow drilling in the North Pit Extension Zone and deeper drilling in the Western Zone. Drilling in the Western Zone is intended to upgrade and expand current mineral resources in support of an updated mineral resource estimate.

Geoff Chinn, VP Business Development and Exploration, added: “Earlier this year, we identified opportunities to expand and upgrade mineral resources, particularly in the North Pit Extension Zone, where shallow drilling could extend mineralization within the current open pit mining shape. The relatively high gold to copper ratio we are seeing in the Pit Zone and North Pit Extension Zone is shifting some of our thinking on low-grade mineral processing. We are pleased to begin reporting drill results from this east-west fence of holes along the southern end of the North Pit Extension Zone and look forward to additional results from this area, along with drill results from the Western and Pit Zones, in the coming weeks and months.”

Kwanika Exploration Drill Hole Summaries

Results for four drill holes are presented on cross-section 6156400 N (Figure 2) with mineralized intersections listed in Table 1 and collar locations provided in Table 2. The cross-section is located at the southern end of the North Pit Extension Zone. The holes were designed to improve confidence in the mineralization by reducing drill hole spacing to approximately 50 metres, test up-dip and down-dip extensions, and evaluate whether drilling toward the west improves geological and grade continuity.

Figure 2: Cross-Section 6156400 N showing 2026 drill results

Figure 2

North Pit Extension:

Hole K-26-303 was drilled with NQ core and sampled on 2-metre intervals from half sawn core and drilled on 270° azimuth at a -50° dip to a depth of 125 metres.

After 45 metres of overburden the hole intersected beige mineralized potassic altered and fractured monzonite characteristic of higher grades at Kwanika to 114 metres (Comp 1, 2). The interval was overprinted by green propylitic alteration starting at 100 metres and a late monzonite porphyritic dyke was encountered between 114 and 120 metres. The hole ended in green propylitic altered monzonite mineralization (comp 3). The hole successfully extended higher-grade mineralization to the north and up-dip, returning a 42 metre intersection correlated to unit 10.

Hole K-26-304 was drilled with NQ core and sampled on 2-metre intervals from half sawn core and drilled on 270° azimuth at a -55° dip to a depth of 126 metres.

After 39 metres of overburden the hole intersected a grey late porphyritic dyke. A grey and pink weakly mineralized monzodiorite was then encountered between 43 and 70 metres (Comp 4) followed by a weakly mineralized green propylitic altered dyke crosscut by planer quartz-anhydrite veins associated with pyrite and magnetite (Comp 5). The hole intersected 16 metres of near-surface copper dominant low-grade mineralization that can be correlated to adjacent sections, thereby extending mineralization.

Hole K-26-312 was drilled with NQ core and sampled on 2-metre intervals from half sawn core and drilled on 270° azimuth at a -50° dip to a depth of 150 metres. The hole deviated immediately to -37° and then reverted to its planned dip, which is under review.

After 45 metres of overburden the hole intersected pink and green propylitic altered monzodiorite and at 53 metres green propylitic altered andesite, including a no core recovery between 66 and 69 metres. At 76 metres, the hole encountered pink potassic altered monzonite to 84 metres, green diorite to 92 metres and orange and green monzodiorite to 110 metres. A pink weakly mineralized potassic altered monzonite was intersected between 110 and 117 metres (Comp 6) followed by an unmineralized brown andesite to 120 metres. Low-grade mineralization in beige potassic altered monzonite containing irregular quartz veins was intersected between 120 and 141 metres, followed by unmineralized monzodiorite interval to 145 metres, then back in to mineralized potassic altered monzonite to the end of hole (Comp 7). The hole successfully infilled higher-grade gold dominant mineralization correlated with Unit 10 by returning a 27 metres intersection. The hole, however, downgraded mineralization above this unit.

Hole K-26-340 was drilled with NQ core and sampled on 2-metre intervals from half sawn core and drilled on 270° azimuth at a -50° dip to a depth of 324 metres.

After 42 metres of overburden the hole intersected fractured green propylitic altered monzonite crosscut by thick white quartz veins. A major fault is encountered between 78 and 85 metres followed by alternating intervals of fractured green and orange propylitic altered monzonite and a related tectonic breccia. Between 164 and 176 metres green and orange monzodiorite is intersected followed by a tectonic breccia hosting low-grade copper-gold mineralization to 196 metres (Comp 8). Mineralization continues in beige potassic altered monzonite porphyry crosscut by quartz-tourmaline veins to 218 metres (Comp 8) and then an orange and green monzodiorite interval to 292 metres, including weak gold mineralization between 242 and 258 metres (Comp 9). A late dyke crosscuts this unit between 292 and 301 metres with mineralized beige potassic altered monzonite encountered thereafter to the end of hole at 324 metres (Comp 10). The hole did not intersect Unit 10 suggesting a fault termination immediately to the west of it. The hole, however, confirms deep low-grade gold dominant mineralization under Unit 10 by returning a 47 metre intersection.

Overall, drilling on Section 6156400 N are consistent with east dipping mineralized trends supporting drilling the deposit with towards the west with moderately dipping holes.

Table 1: Drill Results in this News Release1 2

Comp Hole From To Length Area Cu Au Ag Pd CuEq True
Width
Mineralized
#   (m) (m) (m)   (%) (g/t) (g/t) (g/t) (%) Est. (m) Unit
1 K-26-303 49.0 63.8 14.8 Pit 0.24 0.70 1.17 0.03 1.01 14.3 Higher-Grade Au 10
2 K-26-303 72.6 114.3 41.7 Pit 0.40 0.67 1.65 0.02 1.13 40.2 Higher-Grade Au 10
3 K-26-303 120.3 125.0 4.7 Pit 0.63 0.42 2.29 0.00 1.11 4.5 Lower-Grade Cu 8
4 K-26-304 65.2 69.5 4.3 Pit 0.34 0.11 0.25 0.00 0.46 4.1 Lower-Grade Cu 8
5 K-26-304 82.0 98.0 16.0 Pit 0.31 0.17 0.33 0.01 0.50 15.0 Lower-Grade Cu 8
6 K-26-312 110.4 114.2 3.8 Pit 0.19 0.67 0.99 0.03 0.93 3.6 Lower-Grade Cu 8
7 K-26-312 122.9 150.0 27.2 Pit 0.20 0.64 0.98 0.02 0.90 26.2 Lower-Grade Cu 8
8 K-26-340 169.6 217.0 47.4 Pit 0.30 0.44 1.23 0.02 0.78 45.8 Lower-Grade Cu 8
9 K-26-340 242.0 258.0 16.0 Pit 0.14 0.38 0.76 0.04 0.56 15.5 Lower-Grade Cu 8
10 K-26-340 318.0 324.0 6.0 Pit 0.29 0.30 0.93 0.00 0.62 5.8 Lower-Grade Cu 8


Table 2: Drill Collar Information
3

Hole Collar X Collar Y Collar Z Collar Azimuth Collar Dip Final Length Core Size
K-26-303 351598 6156407 1007 270 -50 125 NQ
K-26-304 351512 6156412 1012 270 -55 126 NQ
K-26-312 351650 6156400 1005 270 -50 150 NQ
K-26-340 351698 6156401 1010 270 -50 324 NQ


Quality Assurance / Quality Control

Drilling at Kwanika in 2026 was designed and supervised by NorthWest and implemented by InData Geoscience with assay QA/QC checks by Explore Geosolutions. Samples were collected, tracked and an external QA/QC program was implemented using coarse blanks and certified prepared blanks and standards to monitor analytical accuracy and precision. The samples were sealed on site and shipped to Activation Laboratories Ltd. (“Actlabs”) in Kamloops, BC. The laboratory’s internal quality control system complies with global certifications for quality ISO 17025. Drill core samples were analyzed using a combination of Actlabs multi-element 1F2 analysis for low level concentrations (4-Acid Digestion, ICP-OES) and the 8-4 Acid ICP-OES analysis for higher level concentrations (4-Acid Digestion, ICP-OES with automatic over limits for base metals and silver). Gold, platinum and palladium assaying was completed with 1C-OES method, using a 30-gram fire assay with ICP finish analysis. In addition, about 5% of the sample pulps are re-assayed at a secondary laboratory to confirm reproducibility and check for bias.

Technical aspects of this news release have been reviewed, verified, and approved by Geoff Chinn, P.Geo., VP Business Development and Exploration for NorthWest, who is a qualified person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

About NorthWest:

NorthWest is a copper-gold exploration and development company with a pipeline of advanced and early-stage projects in British Columbia, including Kwanika-Stardust, Lorraine-Top Cat and East Niv. With a robust portfolio in an established mining jurisdiction, NorthWest is well positioned to participate fully in strengthening global copper and gold markets. The Company is committed to responsible mineral exploration, working collaboratively with First Nations to help ensure future development incorporates stewardship best practices and respects traditional land use. Additional information can be found on the Company’s website at www.northwestcopper.ca.

On Behalf of NorthWest
“Paul Olmsted”
CEO, NorthWest Copper

For further information, please contact: 
416-457-3333
info@northwestcopper.ca  

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Information 

 This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussion with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often, but not always using phrases such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to statements with respect to; plans and intentions of the Company; proposed exploration and development of NorthWest’s exploration property interests; the Company’s ability to finance future operations; mine plans; magnitude or quality of mineral deposits; the development, operational and economic results of current and future potential economic studies; adding the Lorraine resource to the Kwanika-Stardust Project; the Company’s current goals; geological interpretations; the estimation of Mineral Resources; anticipated advancement of mineral properties or programs; future exploration prospects; the completion and timing of technical reports; future growth potential of NorthWest; and future development plans.

All statements, other than statements of historical fact, included herein, constitutes forward-looking information. Although NorthWest believes that the expectations reflected in such forward-looking information and/or information are reasonable, undue reliance should not be placed on forward-looking information since NorthWest can give no assurance that such expectations will prove to be correct. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information, including the risks, uncertainties and other factors identified in NorthWest’s periodic filings with Canadian securities regulators. Forward-looking information are subject to business and economic risks and uncertainties and other factors that could cause actual results of operations to differ materially from those contained in the forward-looking information. Important factors that could cause actual results to differ materially from NorthWest’s expectations include risks associated with the business of NorthWest; risks related to reliance on technical information provided by NorthWest; risks related to exploration and potential development of the Company’s mineral properties; business and economic conditions in the mining industry generally; fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of drill results and the geology, continuity and grade of mineral deposits; the need for cooperation of government agencies and First Nation groups in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; and other risk factors as detailed from time to time and additional risks identified in NorthWest’s filings with Canadian securities regulators on SEDAR+ in Canada (available at www.sedarplus.com). 

Forward-looking information is based on estimates and opinions of management at the date the information is made. NorthWest does not undertake any obligation to update forward-looking information except as required by applicable securities laws. Investors should not place undue reliance on forward-looking information.

________________________________________
1 Estimated true widths based on collar azimuth and dip and the average dip of the mineralized zone
2 CuEq assumes metal prices of $3,100/oz gold, $4.50/lb copper, $36/oz silver and $1,100/oz palladium metal recoveries of 96% gold, 90% copper, 96% silver, 0% palladium and calculated as follows: Cu +100* ( (Au /31.1035 * Au Price * Au Rec) / (Cu Price * 2204.62 * Cu Rec) + (Ag /31.1035 * Ag Price * Ag Rec) / (Cu Price*2204.62 * Cu Rec) + (Pd /31.1035 * Pd Price * Pd Rec) / (Cu Price*2204.62 * Cu Rec) )
3 Collar coordinates reference UTM Zone 10N NAD83.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/00a90380-a8ca-430c-b6e2-30fa790e0693

https://www.globenewswire.com/NewsRoom/AttachmentNg/48fd42d4-0cf6-482e-9a01-7b0a6d16b923

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Gamma Communications Plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Joint Broker to Gamma Communications Plc
(d)        Date dealing undertaken: 06th October 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales Total number of securities Highest price per unit paid/received Lowest price per unit paid/received
Ordinary shares Purchases 224,083 1092 1091
Ordinary shares Sales 203,612 1093 1091.5

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION
        
(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 07th October 2026
Contact name: Abhishek Gawde
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Gooch & Housego plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor and Broker to Gooch & Housego plc
(d)        Date dealing undertaken: 06th October 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales Total number of securities Highest price per unit paid/received Lowest price per unit paid/received
Ordinary shares Sales 2,284 1230 1230

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 07th October 2026
Contact name: Abhishek Gawde
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

SEATTLE, Oct. 07, 2026 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that data from the Company’s [²¹²Pb]VMT-α-NET program have been accepted for presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium taking place November 5 to 7, 2026, in Las Vegas, Nevada.

Presenter Abstract Title Presentation Details
Thorvardur Halfdanarson, MD, Mayo Clinic Rochester Cohort level safety and efficacy results for [212Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroendocrine tumors (NETs): Cohorts 1–3 Abstract Number: 36595
Presentation type: Oral presentation
Session Name: Featured Abstracts I: Evolving Therapies, Risks, and Outcomes in NETs
Date: November 5, 2026
Time: 4:10 pm – 5:25 pm PST


About [²¹²Pb]VMT-α-NET

Perspective designed [212Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or ²¹²Pb, to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies (RPT).

Interim clinical data from the study, with a data cut-off date of April 17, 2026, were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2026. These data included efficacy results for half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and patients in Cohorts 3 and 4 are pending. The Company plans to submit additional data for presentation at future medical conferences in 2026 and 2027.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary 224Ra/212Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company’s website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s preclinical and clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s beliefs that its product candidates address certain unmet medical needs; the Company’s expectations regarding regulatory pathways for its product candidates; the Company’s expectations regarding its interactions with regulatory agencies and the expected timing thereof; the Company’s regional distribution and manufacturing capabilities; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

ENTENTE Network of Companies
Katie Morris, PhD
katiemorris@ententeinc.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.